Adam Koppel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
The Reporting Person resigned from the Board of Directors of Foghorn Therapeutics Inc., effective December 29, 2024. This Form 4 is being filed solely as a voluntary exit Form 4 indicating that no further reporting will be required of the Reporting Person.